Research programme: vitamin D3 analogues - BioXell/Galapagos

Drug Profile

Research programme: vitamin D3 analogues - BioXell/Galapagos

Alternative Names: BXL 055; BXL 082; BXL 083; BXL 093

Latest Information Update: 27 May 2009

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator BioXell SpA; Galapagos NV
  • Class Cholestenes; Vitamin D analogues
  • Mechanism of Action Calcitriol receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Hyperparathyroidism; Osteoporosis

Most Recent Events

  • 25 Jul 2007 Preclinical development is ongoing
  • 22 Sep 2004 ProSkelia has merged with Strakan to form ProStrakan
  • 01 Apr 2004 Preclinical trials in Hyperparathyroidism in Europe (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top